Human genetics exposes a long list of druggable leads in valvular heart disease
Valvular heart disease has long been treated as a mechanical problem first and a pharmacologic problem second. Once stenosis or regurgitation becomes severe, the therapeutic conversation usually turns toward valve repair or replacement, because no medication has convincingly altered the disease course across the full spectrum of valvular heart disease. This integrative evidence synthesis takes a different route: it starts with human genetic associations, links those signals to druggable biology, and then asks which compounds already have clinical or translational support.
The result is not a finished treatment map. It is a structured list of biologically plausible targets, with a clear emphasis on where genetic evidence, tissue relevance, and real-world pharmacology overlap.
1464 genetic associations narrowed to a tractable target set
Investigators pulled valvular heart disease-associated variants from the NHGRI-EBI Genome-Wide Association Studies Catalogue and Ensembl, then connected annotated genes through the Open Targets Platform. Linked drugs were checked through structured searches of MEDLINE and ClinicalTrials.gov, and the protocol was registered prospectively in PROSPERO.
The search produced 1464 genetic associations, representing 844 unique variants and 582 candidate genes. From that broader pool, 431 genes had tractability information, and 51 had linked compounds. Those 51 targets mapped to 388 distinct pharmacological agents, including 273 compounds already in phase 3 or 4 of clinical development. In other words, the genetic signal did not simply point to rare experimental biology; it intersected with a large existing pharmacologic universe.
Aortic stenosis dominated the linked-drug landscape. That concentration is clinically intuitive. Aortic stenosis is the most intensively studied degenerative valve disorder, and it also offers a clearer path from molecular perturbation to measurable hemodynamic disease than many other valve phenotypes. Calcification, inflammation, extracellular matrix remodeling, and lipid-related pathways can all be traced to specific molecular actors, making the aortic valve a more reachable target for genetics-guided repurposing than a diffuse or purely degenerative framework would suggest.
Aortic stenosis carried most of the repurposing signal
The target list did not translate into equal levels of evidence across all compounds. Clinical evidence supported therapeutic potential for 14 drugs. Another eight had preclinical or mechanistic cardiovascular support, and four carried adverse cardiovascular signals. This split matters because genetic proximity alone does not guarantee safety or benefit. A locus may be biologically relevant without being therapeutically favorable, and a compound may hit a plausible target while still worsening hemodynamics, arrhythmia risk, or vascular injury.
One practical implication follows immediately: a genetics-first approach can expand the drug pipeline, but it also has to screen out biologic dead ends and harmful repurposing candidates before they ever reach a valve-specific trial.
The evidence-weighted framework used here tried to do exactly that. Targets were prioritized by genetic-functional support, tissue and mechanistic context, and translational tractability. That layered approach is more rigorous than simply collecting associated genes and listing existing drugs beside them. It reflects a bedside truth familiar to clinicians who manage valve disease: not every pathway that appears in a sequencing study deserves the same degree of therapeutic confidence.
Why genetics can matter in a disease defined by anatomy
Valve disease often seems structurally fixed once symptoms arrive, but the biology begins long before the valve becomes critically narrowed or leaky. Human genetics can expose the pathways that govern calcification, fibrosis, lipid handling, inflammation, and matrix turnover years before symptoms surface. If a gene repeatedly appears across association studies and also maps to a druggable protein, the pathway becomes more than a statistical signal; it becomes a candidate intervention point.
That is especially relevant in aortic stenosis, where calcific remodeling narrows the valve orifice over time and progressive pressure overload drives left ventricular consequences. Drugs that influence upstream biology may not reverse established mechanical obstruction, but they could still alter progression rate, inflammatory tone, or the local milieu that fosters calcification. The study does not claim those effects have been proven. It shows where the hypothesis is strongest and where existing pharmacology already intersects with human genetic support.
The translational value is also uneven by design. Some targets may be more useful for prevention than for treatment of advanced disease. Others may matter only in subgroups defined by valve phenotype, concomitant atherosclerotic risk, or tissue-specific expression. A genetics-informed ranking system helps sort those possibilities before expensive interventional studies begin.
The gap between supported targets and available therapies remains wide
The clearest message from this synthesis is the gap itself. Hundreds of drug-linked agents sat downstream of genetic associations, yet only 14 had clinical evidence strong enough to support therapeutic potential in this review framework. Even among the most promising candidates, the evidence base was a mix of human genetics, mechanistic data, preclinical work, and broader cardiovascular experience rather than dedicated valve-outcome trials.
That gap explains why valvular heart disease still lacks disease-modifying drug therapy. The field has plenty of hypotheses and far fewer prospective tests. It also helps explain why valve pharmacotherapy has been slow to mature compared with coronary disease or heart failure, where drug development could lean on more direct biomarkers, established event rates, and easier biologic readouts. Valve lesions progress over years, and the endpoint is often intervention rather than a clean pharmacologic surrogate.
For trial design, this creates a difficult but useful mandate. Future studies will need precise phenotyping, careful selection of disease stage, and a willingness to test whether a repurposed compound can slow structural progression rather than simply modify symptoms or laboratory markers. A genetics-informed prioritization system gives those studies a rational starting point.
The next step is mechanistic validation, not immediate repurposing
This evidence synthesis is best read as a hypothesis-generating atlas of the valve druggable space. It does not prove efficacy for any compound in routine care, and it does not replace randomized outcomes data. What it does provide is a disciplined bridge between human genetics and clinical pharmacology, which is exactly the kind of bridge needed when a disease has been treated as surgically inevitable for decades.
The funding base for the work was broad, spanning Limburg Clinical Research Centre of UHasselt, Jessa and ZOL; the British Heart Foundation; the National Institute for Health and Care Research; UK Research and Innovation; the European Research Council; and Horizon Europe. That support matches the scale of the problem. Valve disease is common, biologically heterogeneous, and still waiting for a therapy that changes the trajectory before the anatomy becomes irreversible.
For now, the most concrete output is a ranked set of targets and compounds, especially in aortic stenosis, where the concentration of drug-linked biology was strongest. The unresolved question is not whether valve disease has actionable pathways—it clearly does—but which of those pathways can be converted into safe, durable clinical benefit in patients before the valve is beyond pharmacologic rescue.